Used in targeted immunotherapy for B-cell malignancies such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Binds specifically to CD22, a surface antigen on malignant B cells, enabling immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Investigated as a component of antibody-drug conjugates (ADCs) to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. Also utilized in flow cytometry and immunohistochemistry for diagnostic detection and monitoring of B-cell cancers. Supports research into autoimmune diseases by modulating B-cell activity through CD22 signaling pathways.